3 SECRET-ITN ESRs seconding at the Oncoproteomics Center at the Medical University VUmc in Amsterdam
Despite significant hurdles posed by the COVID-19 pandemic travel constraints, three of the SECRET ITN ESRs managed to organise and begin their secondments at the beneficiary VUmc in Amsterdam. Elena Gutiérrez Galindo (ESR 2), working on uncovering the impact of biomechanical ECM properties on Golgi-controlled cancer cell secretion and communication, and Merih Özverin (ESR3) working on aberrant Rho regulation in cancer cell secretion, are both hosted at the University of Stuttgart, while Alexia Maria Gali (ESR 14) is focusing on pathway construction via multiplex phosphoproteomic data at ProtATonce in Greece. They all began their secondment at the Oncoproeomics lab headed by Prof. Connie Jimenez in the beginning of March, starting off by attending the digital and hand-on proteomics workshop, followed by a more in depth preparation for the analysis of their prepared samples.
Workshop Proteomics (15.-19.03.2021)
The SECRET ITN ESRs were offered the opportunity to join a one week digital workshop focusing on proteomics, an optional training event kindly organised by our beneficiary, Prof. Connie Jimenez from the OncoProteomics Laboratory at the VU University Medical Center Amsterdam. The workshop coincided with the beginning of three of the ESR secondments in the Jimenez lab.
All ESRs were encouraged to join the digital lectures and interactive workshops of the week, while the three seconding ESRs found on location could continue with the training face-to-face on the following week. An optional exam at the end of the course gave the students the additional possibility to gain extra credit points for the attendance.
(Fig. Adapted from Suriniva et al., J.Proteome.Res. 10(1), 5-16 (7-1-2011))
SECRET-ITN seminar – February session (23.02.2021)
Our SECRET-ITN seminar for the month of February focused on the private sector, with insightful talks from Leonidas Alexopoulos, founder of Protavio (UK) /ProtATonce (GR) and from Judith Farrés Marisch, Head of Collaborative Research at Anaxomics in Barcelona.
Leonida’s talk was titled “Network-based computational and experimental tools for compound & biomarker assessment“. The company ProtATonce was founded end of 2011 and expanded via the affiliated company Protavio in UK is 2016. Today ProtATonce and affiliate company Protavio operates in Greece and UK and offers smart, innovative products and services on regular & multiplex assays with state of the art facilities. ProtATonce harnesses the power of multiplex technology on Luminex (TM) and other multi-omics technologies and offers novel products and services for biomarker discovery, companion diagnostics, serology, patient stratification, and compound evaluation. The ProtATonce GMP, ISO13485, and ISO9001 compliant quality management system translates your discovery idea to an IVD product.
Anaxomics is a bioinformatics company molecularly modelling human physiology through Systems Biology and Artificial Intelligence. Judith, in her talk: “Connecting phenotypic outcome with molecular level evidences by network analysis”, explained how their mathematical models of patients (either real or objective of study) allow the integration of experimental data (e.g. Big Data, omics data) with a proprietary translational database of clinical effectors, and offers virtual experimentation yielding faster, more economic, more insightful results. The goal of Anaxomics is to help the biopharma industry to maximize the value of their discovery and clinical development by leveraging the potential indications of all the compounds in their pipeline, and by identifying and minimizing their potential safety risks.
New review article from SECRET-ITN beneficiary MUW published!
Mapping the Metabolic Networks of Tumor Cells and Cancer-Associated Fibroblasts
Prof. Helmut Dolznig, principal investigator at the Institute of Medical Genetics at the Medical University of Vienna (beneficiary MUW), contributed to an exciting new publication in the framework of the SECRET Horizon 2020 funding. The publication highlights the metabolic landscape of tumour cells and cancer-associated fibroblasts (CAFs), including their recently identified subtypes, in different tumour types, and offers a comprehensive overview of various in vitro and in vivo metabolic techniques as well as different in silico computational tools that can be used to identify and characterise CAF–tumour cell interactions. Full open access text